Hemisynthetic trifluralin analogues incorporated in liposomes for the treatment of leishmanial infections
- Autores: Alexandra Esteves M, Armanda Rodrigues M, Carvalheiro M, Cruz MEM, Eleuterio CV, Lopes RM, Santos-Gomes G, Santos-Mateus D, Scoulica E
- Ano de Publicação: 2015
- Journal: European Journal of Pharmaceutics and Biopharmaceutics
- Link: http://www.ncbi.nlm.nih.gov/pubmed/25936854
Leishmaniasis, a vector-borne parasitic disease caused by Leishmania protozoa, is one of the most neglected tropical diseases in terms of drug discovery and development. Current treatment is based on a limited number of chemotherapeutic agents all of which present either/or resistance issues, severe toxicities and adverse reactions associated with extended treatment regimens, and high cost of therapy.